FDA's cancer chief weighs in on common chemo shortages — report

Tyler Patchen

News Reporter

Richard Pazdur, director of the FDA’s Oncology Center of Excellence, attributes the current shortage of two cancer drugs to drug companies that haven’t invested in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA's cancer chief weighs in on common chemo shortages — report

Tyler Patchen

News Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

US drugs rely heavily on ingredients made overseas, new report shows

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne

Netherlands pours $1.5B into biotech in pursuit of global leadership ambitions

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

FDA's can­cer chief weighs in on com­mon chemo short­ages — re­port

News Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

FDA's cancer chief weighs in on common chemo shortages — report